<DOC>
	<DOCNO>NCT01552239</DOCNO>
	<brief_summary>RATIONALE : Modern radiotherapy technique neoadjuvant set potential minimize morbidity maximize efficacy . An additional boost dose provide locally HDR-brachytherapy patient positive margin tumor resection . PURPOSE : This phase II trial study safety efficacy combination modern radiotherapy element apply tumor small volume surround normal tissue ( IMRT , IGRT ; brachytherapy case positive resection margin ) see well work treat patient High-Risk Soft Tissue Sarcoma Extremities .</brief_summary>
	<brief_title>Preoperative Radiotherapy Sarcomas Extremities With Intensity-Modulation , Image-Guidance Small Safety-margins</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Histologic radiographic proof localize highrisk soft tissue sarcoma meeting follow criterion : Lesion originate extremity upper extremity lesion may occur medial border scapula tumor far distal finger tip low extremity region include hip girdle tumor commence iliac crest , exclude lesion arise within pelvis , extend include lesion far distal toe AJCC Stage II III disease ( except T1atumors N1 ) Primary presentation local recurrence biopsy inadequate surgery result residual tumor crosssectional imaging Tumors must consider resectable accord cross sectional imaging , potentially resectable preoperative radiotherapy ECOG Performance Status 02 Informed Consent Diagnosis follow : Primitive neuroectodermal tumor Soft tissue Ewing ` sarcoma Extraskeletal osteo chondrosarcoma Aggressive fibromatosis ( desmoid tumor ) Dermatofibrosarcoma protuberans Regional nodal disease unequivocal distant metastasis Life expectancy &lt; 1 year Pregnancy Major medical illness would preclude study treatment History major wound complication recurrent skin infection Known HIV positivity &lt; 2 week elapse prior surgery cytotoxic chemotherapy persist acute toxicity &gt; grade 1 tumorbearing limb result prior treatment anticancer modality Cytotoxic chemotherapy , target therapy investigational agent concurrent study treatment Prior radiotherapy site present STS . Chronic requirement treatment immunoÂ¬suppressive agent steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>Intensity-Modulated Radiation Therapy ( IMRT )</keyword>
	<keyword>Tomotherapy</keyword>
	<keyword>Safety Margins</keyword>
	<keyword>Image-guided Radiation Therapy</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>interstitial</keyword>
</DOC>